Abstract 206P
Background
To compare discriminant ability of risk stratifications for prostate cancer in three authoritative guidelines: National Comprehensive Cancer Network clinical practice guideline (NCCN-g), American Urological Association / American Society for Therapeutic Radiology and Oncology/ Society of Urologic Oncology Guideline(AUA-g) and European Association of Urology- European association of nuclear medicine- European Society for Radiotherapy and Oncology- European Society of Urogenital Radiology- International Society of Geriatric Oncology guideline(EAU-g).
Methods
511916 patients with one primary prostate cancer diagnosed between 2004 and 2016 were identified using the Surveillance, Epidemiology, and End Results (SEER, submitted in) database of the National Cancer Institute. Patients were excluded from analysis if < 18 years of age, not adenocarcinoma, diagnosed at autopsy or death certificate only, with an unknown follow-up, incomplete clinical and demographic information, leaving 287333 patients in this cohort. Patients were categorized as different risk stratifications by three latest guidelines (NCCN-g, AUA-g and EAU-g) respectively. Follow-up endpoint was prostate cancer specific mortality (PCSM), cutoff date was December 31, 2016. Kaplan–Meier analysis, multivariable Cox regression and area under the receiver operating characteristics (ROC) curve (AUC) analyses were performed.
Results
The 287333 patients are all from 2004 to 2015. Median follow-up was 69 months (IQR: 39-104). For the three risk stratification modalities, all 6 risk groups in NCCN-g, 5 risk groups in AUA-g and 5 risk groups in EAU-g independently predicted PCSM. NCCN-g yielded 3.1-fold HR differences between low risk group and intermediate risk group, 14.8-fold HR differences between low risk group and high risk group, 33.0-fold HR differences between low risk group and very high risk group, 56.2-fold HR differences between low risk group and regional group, and 148.9-fold HR differences between low risk group and metastatic group. AUC is 0.8332, 0.8309 and 0.7868 in NCCN-g, AUA-g and EAU-g.
Conclusions
This large population-based analysis confirms the better discriminant properties of the risk stratification method in NCCN guideline.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Peking University First Hospital radiation oncology department.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract